Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COIN-B: Intermittent vs Continuous Cetuximab in mCRC
NCT00640081Phase 2Completed
- Start
- Jul 2007
- Primary completion
- Jun 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of cetuximab in metastatic colorectal cancer (mCRC) (2 arms). Primary endpoint: Failure-free survival at 10 months. Started Jul 2007; status: completed.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00640081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00640081.